50% Gains Investing Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 50% Gains Investing

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dale Baker who wrote (7880)	6/24/1999 7:42:00 AM
From: gringodoc	Read Replies (2) of 118717

Dale: IMO, Biomatrix's Synvisc is no panacea to osteoarthritis. I've had a short position in BXM for several months and I'm looking for single digits in the future. Two rheumatologists to whom I've spoken stopped using the product months ago because of mediocre response and also because they did not wish to carry expensive inventory in their office. None of the medical literature that I've reviewed has impressed me with this one. Some insurance companies are also balking at paying for the product. Personally, I feel that BXM will follow the VVUS story and chart to the tee: »»» both firms are essentially one trick ponies »»» both firms have FDA approved products that work, but work poorly »»» both MUSE and Synvisc are invasive Rx's »»» the stocks of both firms popped significantly when FDA approved their manufacturing site and they brought production in house. '''''''''' I feel that demand has been largely overestimated and that Biomatrix will now be saddled with excess capacity etc etc etc Gringo

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next